GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » Peter Lynch Fair Value

Innophos Holdings (Innophos Holdings) Peter Lynch Fair Value : N/A (As of Apr. 29, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Innophos Holdings Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Innophos Holdings's Peter Lynch Fair Value or its related term are showing as below:



IPHS's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Chemicals industry.
Industry Median: 1.255
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Innophos Holdings Peter Lynch Fair Value Historical Data

The historical data trend for Innophos Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innophos Holdings Peter Lynch Fair Value Chart

Innophos Holdings Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Innophos Holdings Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Innophos Holdings's Peter Lynch Fair Value

For the Specialty Chemicals subindustry, Innophos Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innophos Holdings's Price-to-Peter-Lynch-Fair-Value Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Innophos Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Innophos Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



Innophos Holdings Peter Lynch Fair Value Calculation

Innophos Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *1.07
=N/A

Innophos Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.07.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Innophos Holdings  (NAS:IPHS) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Innophos Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=31.99/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innophos Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Innophos Holdings (Innophos Holdings) Business Description

Traded in Other Exchanges
N/A
Address
259 Prospect Plains Road, Cranbury, NJ, USA, 08512
Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.
Executives
John M Steitz director ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink director, officer: Chairman, CEO, President 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline director 50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar director C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo officer: Sr. VP, Mfg, Eng & EH&S 15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas director 1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld officer: Senior VP and CFO 259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie director 5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress director, officer: CEO 259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide director BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse officer: VP-Chief Financial Officer 259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp 10 percent owner JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116

Innophos Holdings (Innophos Holdings) Headlines